Moderna's Cancer Vaccine Shows Promise Against Deadliest Skin Cancer Type

A breakthrough vaccine from Moderna could be the answer to the deadliest skin cancer type after showing promise in clinical trials conducted by scientists.

At a medical meeting on Saturday, researchers presented their study on an experimental mRNA vaccine by Moderna coupled with Merck's blockbuster immunotherapy Keytruda.

According to the team, the combination of the vaccine and the therapy cut the risk of death or recurrence of melanoma by 44% compared to using Keytruda alone.

"From a general cancer therapeutic standpoint, this is a potential major breakthrough," Mass General Cancer's melanoma expert Dr. Ryan Sullivan said in a statement obtained by CNBC.

Sullivan and his colleagues observed that the mRNA vaccine worked well with Keytruda, which is designed to rev up the immune system. Their combination helped prolong the time patients have without having a recurrence or death.

The study findings were presented by Dr. Jeffrey Weber of the NYU Langone Perlmutter Cancer Center at the American Association for Cancer Research meeting in Orlando, Florida, this weekend.

The presentation highlighted that Moderna's cancer vaccine is custom-built. The scientists developed the dose after a thorough analysis of a patient's tumor following surgical removal.

Each vaccine is designed to train the immune system to recognize and target only the specific mutations in cancer cells. For the midstage trial, the team used the combo in participating men and women with a high risk of their melanoma recurring.

The experiment was not free from side effects. Most of the patients reported fatigue after receiving the vaccine.

Moderna and Merck are now discussing with U.S. regulators about moving forward with a late-stage trial. However, the results of larger trials could take three to four years.

Source: medicaldaily.com